REOLYSIN® is a proprietary variant of the reovirus, an acronym for Respiratory Enteric Orphan Virus. In clinical trials, REOLYSIN® has been shown to be well-tolerated, with patients exhibiting only mild, flu-like symptoms. REOLYSIN® has been used alone and in combination with biologics, chemotherapy and radiotherapy for various cancers.